Q-omics provides the consensus-scored CRTC3 profile across patient tissues and cancer cell-line models. CRTC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRTC3 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, CRTC3 protein abundance shows 24,730 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, THCA, and UCEC as cancer lineages where CRTC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRTC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRTC3 survival associations across molecular data types. CRTC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRTC3 RNA expression–survival associations across cancer types. High CRTC3 expression shows unfavorable associations in KICH, BLCA and ACC, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CRTC3 RNA expression.
This table summarizes CRTC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CRTC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRTC3 shows lower tumor expression in THCA and BLCA and higher tumor expression in HNSC, KIRC, LIHC and CHOL. The THCA box plot shows higher CRTC3 RNA expression in normal versus tumor tissue (log2 FC = −0.586, t-test p < 0.001).
This table shows molecular features associated with CRTC3 in patient tissues and cancer cell lines. In patient samples, CRTC3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, CRTC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
